
Inventiva S.A. (IVA) Stock Forecast & Price Target
Inventiva S.A. (IVA) Analyst Ratings
Bulls say
Inventiva SA is a biopharmaceutical company focused on developing lanifibranor for the treatment of non-alcoholic steatohepatitis (NASH), addressing a significant unmet medical need as there are currently no approved therapies for this condition. The encouraging clinical trial data shows that lanifibranor may provide considerable benefits, including fibrosis improvement and metabolic advantages, positioning it as a potentially best-in-class treatment that could enhance its market adoption in endocrinology and cardiometabolic clinics. Additionally, strong revenue generation from research partnerships with AbbVie and BI supports Inventiva's financial stability and growth potential in its clinical-stage research operations.
Bears say
Inventiva SA, a biopharmaceutical company focused on the development of therapies for diseases like NASH, is facing a negative outlook primarily due to significant financial losses, reporting a net loss of €175.9 million, or €1.62 per share. The company's lead product candidate, lanifibranor, is currently in Phase III development, where any adverse efficacy or safety concerns could severely impact share performance and investor confidence. Additional risks include delays in regulatory timelines and challenges in accessing sufficient financing, which may hinder the company's ability to execute its planned operations effectively.
This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.
Inventiva S.A. (IVA) Analyst Forecast & Price Prediction
Start investing in Inventiva S.A. (IVA)
Order type
Buy in
Order amount
Est. shares
0 shares